Attached files
file | filename |
---|---|
EX-32.2 - EX-32.2 - Syros Pharmaceuticals, Inc. | syrs-ex322_7.htm |
EX-32.1 - EX-32.1 - Syros Pharmaceuticals, Inc. | syrs-ex321_6.htm |
EX-31.2 - EX-31.2 - Syros Pharmaceuticals, Inc. | syrs-ex312_11.htm |
EX-31.1 - EX-31.1 - Syros Pharmaceuticals, Inc. | syrs-ex311_13.htm |
EX-10.22 - EX-10.22 - Syros Pharmaceuticals, Inc. | syrs-ex1022_745.htm |
EX-10.21 - EX-10.21 - Syros Pharmaceuticals, Inc. | syrs-ex1021_720.htm |
EX-10.14 - EX-10.14 - Syros Pharmaceuticals, Inc. | syrs-ex1014_774.htm |
EX-4.1 - EX-4.1 - Syros Pharmaceuticals, Inc. | syrs-ex41_719.htm |
10-K - 10-K - Syros Pharmaceuticals, Inc. | syrs-10k_20191231.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
|
1. |
Registration Statement (Form S-8 No. 333-212363) pertaining to the 2012 Equity Incentive Plan, 2016 Stock Incentive Plan, and 2016 Employee Stock Purchase Plan of Syros Pharmaceuticals, Inc., |
|
2. |
Registration Statements (Form S-8 Nos. 333-216821, 333-223574, and 333-230116) pertaining to the 2016 Stock Incentive Plan and 2016 Employee Stock Purchase Plan of Syros Pharmaceuticals, Inc., |
|
3. |
Registration Statement (Form S-3 No. 333-222634) of Syros Pharmaceuticals, Inc., and |
|
4. |
Registration Statement (Form S-3 No. 333-219369) of Syros Pharmaceuticals, Inc. |
of our report dated March 5, 2020, with respect to the consolidated financial statements of Syros Pharmaceuticals, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2019.
|
|
/s/ Ernst & Young LLP |
|
|
|
Boston, Massachusetts |
|
|
March 5, 2020 |
|
|